查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1807515

感染疾病体外诊断市场（按产品、技术、病原体、应用和最终用户划分）—2025-2030 年全球预测

Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Pathogen, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年感染疾病体外诊断市值将达251.3亿美元，2025年将达266.2亿美元，复合年增长率为6.14%，到2030年将达359.5亿美元。

主要市场统计数据
基准年2024年 251.3亿美元
预计2025年 266.2亿美元
预计2030年 359.5亿美元
复合年增长率（%） 6.14%

在快速病原体鑑定可能决定疫情是否已控制的环境下，感染疾病的体外诊断已成为公共卫生基础设施的关键。实验室决策者越来越依赖先进的仪器和整合服务解决方案来提供及时、准确且经济高效的结果。在新分子技术、自动化数位资料管理整合的推动下，该领域正在经历重大变革，从基础的微生物培养基发展到先进的次世代定序平台。

此外，公共卫生机构和医疗保健提供者要求在不牺牲灵敏度或特异性的情况下提高通量。这推动了试剂化学、检测方法设计和仪器人体工学的持续创新。同时，世界各地的监管机构正在完善核准途径，优先考虑诊断准确性和病人安全，这进一步凸显了对稳健品管系统的需求。因此，产业相关人员必须在复杂的竞争格局中探索，同时利用新兴技术的潜力来保持竞争力，并满足全球对快速感染疾病监测和应对的需求。

一个关键的技术、监管和市场采用的转折点，将重新定义全球感染疾病体外诊断策略

随着新技术的普及和法律规范的演变，感染疾病体外诊断领域正在经历模式转移。等温扩增和高通量定序的进步使得病原体检测更快、更全面，而数免疫检测平台则整合了人工智慧，以增强结果解读。因此，分散式检查模式正在兴起，使诊断能力更贴近照护现场，并且能够制定更早的干预策略。

2025 年美国关税对感染疾病体外诊断产业供应链、成本与竞争动态的影响

美国将于2025年生效的新关税将对进口诊断设备和耗材造成巨大的成本压力。实验室和诊断公司正努力应对自动化培养系统、免疫检测分析仪和分子检测试剂采购成本的上升。因此，许多公司正在重新评估其供应商组合和筹资策略，以减轻供应链中断的影响并维持财务韧性。

来自主要市场细分的洞察揭示了感染疾病体外诊断的产品、技术、病原体、应用和最终用户动态

感染疾病诊断产品包括检测仪器、试剂、试剂套件、软体和服务，每一项都在实验室工作流程中发挥至关重要的作用。仪器种类繁多，从自动化微生物培养系统到用于高通量检测的先进免疫检测和PCR分析仪。试剂和套件包括免疫检测检测套组、针对各种病原体优化的微生物培养基，以及专为精确分子扩增设计的高灵敏度PCR试剂。在服务方面，咨询专业知识可指导实验室完成验证流程，资料管理平台可确保安全且有效率地处理大型资料集，维护支援服务可维护仪器效能并最大限度地减少停机时间。

区域分析重点介绍美洲、欧洲、中东和非洲以及亚太地区感染疾病体外诊断领域的机会和挑战

美洲地区在尖端诊断平台的采用方面继续保持领先地位，这得益于其强大的医疗基础设施和充足的公共卫生资金。受大规模筛检计画和持续监测活动需求的推动，该地区正在快速普及自动化免疫检测係统和分子检测解决方案。同时，关税变化和供应链重组正促使企业加强在北美和南美的本地伙伴关係和製造能力。

对感染疾病体外诊断产业成长的关键参与者的创新、合作伙伴关係和扩张计划进行策略性评估

感染疾病诊断领域的领先公司正透过在检测开发、自动化和数位化整合方面的持续创新来推动成长。与仪器製造商和试剂开发商建立策略联盟，正在打造捆绑解决方案，从而简化采购流程并缩短检验时间。同时，收购和合资企业使老牌跨国公司能够拓展其地域市场并获得利基技术，而新兴的专业公司则正在快速分子检测和人工智慧增强免疫检测等高成长领域站稳脚跟。

确定感染疾病体外诊断市场的新兴趋势，并向行业领导者提供可行的建议，以优化营运并获得竞争优势。

为了保持竞争力，产业领导者应优先考虑模组化平台架构，以实现快速部署侦测和无缝扩展。投资灵活的製造流程并建立多层次的供应商网络，可以帮助企业提高供应链的弹性，并减轻未来贸易政策变化的影响。与合约开发和製造合作伙伴的策略合作可以进一步加快产品上市速度，同时降低资本支出。

采用严谨的调查方法，利用资料收集、分析方法和检验流程来支持感染疾病诊断市场研究

本研究综合了大量二手资料的研究结果，包括同行评审期刊、监管出版物和企业资料披露文件。为了检验访谈。定量资料点与案例研究和试点实施中的真实世界证据进行了三角检验，以确保准确性和有效性。

结论重点强调了感染疾病体外诊断相关人员的关键发现、市场影响和策略考虑

总而言之，感染疾病体外诊断市场正处于关键的十字路口，受技术突破、监管格局变化和贸易政策演变的驱动。随着实验室和製造商适应新的关税环境，采购和生产的策略调整可能会变得越来越重要。细分市场洞察凸显了建构涵盖仪器、试剂和数位服务的多元化产品组合的必要性，以满足不同终端用户的需求。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 开发可携式等温扩增系统以支援感染疾病爆发期间的现场部署
  • 采用基于 CRISPR 的诊断技术将彻底改变高特异性的即时病原体检测
  • 分散式近患者检测解决方案的兴起，实现了快速的床边抗菌素抗药性分析
  • 扩展的数免疫检测平台提高了败血症早期生物标记识别的灵敏度
  • 多重 PCR 检测的整合加速了临床环境中新发呼吸道病毒的同时检测
  • 自动化微生物学工作流程中人工智慧驱动的模式识别的出现提高了吞吐量
  • 微流体实验室晶片设备的发展促进了偏远地区媒介传播疾病的现场检测
  • 越来越多地使用次世代定序进行医院感染控制中的全面病原体监测
  • 报销政策的变化推动了大型医疗网络采用高通量血液培养诊断
  • 诊断公司和製药公司合作推动针对性抗病毒治疗的伴随体外诊断检测

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：2025年美国关税的累积影响

第八章感染疾病体外诊断市场（依产品）

  • 装置
    • 自动化培养系统
    • 免疫检测设备
    • PCR设备
  • 试剂和套件
    • 免疫检测套件
    • 微生物培养基
    • PCR试剂
  • 软体和服务
    • 咨询服务
    • 资料管理软体
    • 维护和支援服务

第九章感染疾病体外诊断市场（依技术）

  • 免疫检测
    • 化学冷光免疫检测
    • 酵素结合免疫吸附试验
    • 萤光免疫分析法
    • 横向流动化验
  • 微生物培养
  • 分子诊断
    • 等温扩增
    • 次世代定序
    • 聚合酵素链锁反应

第 10 章感染疾病体外诊断市场（依病原体）

  • 细菌
    • 肠桿菌科
    • 结核分枝桿菌
    • 金黄色葡萄球菌
  • 真菌
  • 寄生虫
  • 病毒性的
    • 肝炎病毒
    • 人类免疫力缺乏病毒
    • 流感病毒

第11章感染疾病体外诊断市场（依应用）

  • 诊断
  • 流行病学监测
  • 监控
  • 筛检

第 12 章感染疾病体外诊断市场（依最终用户）

  • 学术研究机构
  • 诊所
  • 医院
  • 实验室

13.美洲感染疾病体外诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 欧洲、中东和非洲感染疾病体外诊断市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15.亚太感染疾病体外诊断市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • FPNV定位矩阵2024
  • 竞争分析
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Danaher Corporation
    • DiaSorin SpA
    • Epitope Diagnostics, Inc.
    • F. Hoffmann La-Roche Ltd.
    • Grifols, SA
    • Hologic, Inc.
    • Illumina, Inc.
    • InBios International, Inc.
    • Koninklijke Philips NV
    • Merck KGaA
    • Meril Life Sciences Pvt. Ltd.
    • OraSure Technologies, Inc.
    • Qiagen NV
    • Quest Diagnostics
    • Quidel Corporation
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech PLC
    • Vela Diagnostics

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-A339DAEFAD44

The Infectious Diseases In-Vitro Diagnostics Market was valued at USD 25.13 billion in 2024 and is projected to grow to USD 26.62 billion in 2025, with a CAGR of 6.14%, reaching USD 35.95 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 25.13 billion
Estimated Year [2025] USD 26.62 billion
Forecast Year [2030] USD 35.95 billion
CAGR (%) 6.14%

In an environment where rapid pathogen identification can mean the difference between containment and outbreak, in-vitro diagnostics for infectious diseases have become pivotal to public health infrastructure. Laboratory decision-makers are increasingly reliant on advanced instruments and integrated service solutions to deliver timely, accurate, and cost-effective results. Driven by the convergence of novel molecular techniques, automation, and digital data management, the sector is experiencing a profound transformation that extends from basic microbial culture media to sophisticated next-generation sequencing platforms.

Furthermore, public health agencies and healthcare providers are demanding improved throughput without sacrificing sensitivity or specificity. This has spurred continuous innovation in reagent chemistry, assay design, and instrumentation ergonomics. At the same time, regulatory agencies around the world are refining approval pathways, prioritizing diagnostic accuracy and patient safety, which reinforces the need for robust quality management systems. As a result, industry stakeholders must navigate complex compliance landscapes while harnessing the potential of emerging technologies to stay competitive and address global needs for rapid infectious disease surveillance and response.

Critical Transformative Shifts in Technology, Regulation, and Market Adoption Redefining Infectious Diseases In-Vitro Diagnostic Strategies Worldwide

The landscape of infectious diseases in-vitro diagnostics is undergoing a paradigm shift as novel technologies gain traction and regulatory frameworks evolve. Advances in isothermal amplification and high-throughput sequencing are enabling faster, more comprehensive pathogen detection, while digital immunoassay platforms are integrating artificial intelligence to enhance result interpretation. As a result, decentralized testing models are emerging, bringing diagnostic capabilities closer to point-of-care settings and enabling earlier intervention strategies.

Simultaneously, regulatory bodies are harmonizing global approval processes, which facilitates more streamlined market access but also raises the bar for clinical validation and post-market surveillance. This alignment encourages international collaboration, accelerates technology transfer, and drives investment into standardized manufacturing practices. Consequently, stakeholders must recalibrate their development roadmaps and supply chain strategies to accommodate both heightened regulatory scrutiny and the growing demand for rapid, multiplexed diagnostic solutions.

Comprehensive Analysis of the 2025 United States Tariff Effects on Supply Chains, Costs, and Competitive Dynamics within the Infectious Diseases IVD Industry

The implementation of new United States tariff measures in 2025 has introduced significant cost pressures on imported diagnostic instruments and consumables. Laboratories and diagnostic companies are grappling with increased procurement expenses for automated culture systems, immunoassay analyzers, and molecular assay reagents. Consequently, many organizations are reevaluating their vendor portfolios and sourcing strategies to mitigate supply chain disruptions and maintain financial resilience.

In response, several manufacturers have accelerated domestic production initiatives and formed strategic alliances with local suppliers to reduce import dependency. This realignment of supply networks is reshaping the competitive landscape, with vertically integrated firms gaining an advantage through in-house reagent and instrument production. Over the long term, the tariff impact may lead to increased pricing transparency and a shift towards more localized manufacturing footprints, enabling faster response times to emerging public health threats.

Insights from Key Market Segmentation Revealing Distinct Product, Technology, Pathogen, Application, and End User Dynamics in Infectious Diseases IVD

The product spectrum in infectious diseases diagnostics encompasses instruments, reagents and kits, as well as software and services, each playing a vital role in laboratory workflows. Instruments range from automated microbial culture systems to advanced immunoassay and PCR analyzers tailored for high-throughput testing. Reagent and kit offerings include immunoassay test kits, microbial culture media optimized for a variety of pathogens, and highly sensitive PCR reagents designed for precise molecular amplification. On the services side, consulting expertise guides laboratory validation processes, data management platforms ensure secure and efficient handling of large datasets, and maintenance support services uphold instrument performance and minimize downtime.

Technology segmentation reveals the predominance of immunoassays for rapid antigen and antibody detection, microbiology culture techniques for traditional pathogen isolation, and molecular diagnostics for comprehensive genomic analysis. Within immunoassays, modalities such as chemiluminescence, enzyme-linked immunosorbent assays, fluorescence immunoassays, and lateral flow formats each offer distinct operational advantages. Molecular diagnostics extend from isothermal amplification methods to next-generation sequencing and polymerase chain reaction workflows, supporting everything from point-of-care screening to extensive epidemiological studies.

Pathogen-focused insights demonstrate that bacterial testing demand, driven by Enterobacteriaceae, Mycobacterium tuberculosis, and Staphylococcus aureus assays, remains strong alongside viral diagnostics targeting hepatitis, HIV, and influenza viruses. Application-based analysis underscores critical use cases in diagnosis, epidemiological surveillance, ongoing monitoring of treatment efficacy, and large-scale screening initiatives. End-user segmentation highlights that academic research institutions spearhead innovation, clinics and hospitals deliver patient-centric testing, and specialized laboratories provide high-complexity services, collectively forming an ecosystem that responds to evolving infectious disease challenges.

Regional Analysis Unveiling Opportunities and Challenges across Americas, Europe Middle East Africa, and Asia Pacific in Infectious Diseases Diagnostics

The Americas continue to lead in the adoption of cutting-edge diagnostic platforms, supported by robust healthcare infrastructure and extensive funding for public health initiatives. This region exhibits rapid uptake of automated immunoassay systems and molecular testing solutions, driven by the need for large-scale screening programs and ongoing surveillance efforts. At the same time, supply chain recalibrations following tariff changes have prompted companies to strengthen local partnerships and manufacturing capabilities within North and South America.

In Europe, the Middle East, and Africa, regulatory harmonization under the European In-Vitro Diagnostic Regulation is creating a unified framework for product approval, enhancing market predictability. Nonetheless, funding constraints in certain emerging markets and logistical hurdles in remote areas are shaping differential adoption rates. Meanwhile, Asia-Pacific is experiencing remarkable growth due to government-led screening campaigns, expanding laboratory networks in urban centers, and a growing emphasis on cost-effective assay solutions. Local manufacturing ecosystems are evolving rapidly, enabling faster product launches and fostering competitive pricing strategies to meet diverse regional needs.

Strategic Evaluation of Leading Players' Innovation, Partnership, and Expansion Initiatives Driving Growth in the Infectious Diseases In-Vitro Diagnostic Sector

Leading players in the infectious diseases diagnostics space are driving growth through continuous innovation in assay development, automation, and digital integration. Strategic collaborations between instrument manufacturers and reagent developers are forging bundled solutions that simplify procurement and reduce validation timelines. At the same time, acquisitions and joint ventures are enabling established multinationals to expand their geographic footprint and access niche technologies, while emerging specialized firms are carving out positions in high-growth segments such as rapid molecular assays and AI-enhanced immunoassays.

Furthermore, companies are investing in digital health platforms that aggregate testing data to deliver real-time insights into outbreak trends, antimicrobial resistance patterns, and patient outcomes. These initiatives not only enhance end-user engagement but also foster recurring revenue streams through software subscriptions and service contracts. As the competitive landscape intensifies, differentiation will hinge on the ability to offer comprehensive solutions that seamlessly integrate instruments, consumables, and data analytics into a unified diagnostic ecosystem.

Actionable Recommendations for Industry Leaders to Navigate Emerging Trends, Optimize Operations, and Enhance Competitiveness in Infectious Disease IVD Market

To maintain a competitive edge, industry leaders should prioritize modular platform architectures that enable rapid assay deployment and seamless scalability. By investing in flexible manufacturing processes and establishing multi-tiered supplier networks, organizations can enhance supply chain resilience and mitigate the impact of future trade policy shifts. Strategic collaboration with contract development and manufacturing partners can further accelerate time to market while reducing capital outlay.

In parallel, integrating data management and analytics into diagnostic offerings will empower laboratories to derive actionable insights and improve operational efficiency. Companies that foster open interoperability standards and invest in cybersecurity measures will build trust and drive adoption of digital solutions. Moreover, engaging proactively with regulatory bodies to shape evolving frameworks can streamline approval processes and provide early visibility into compliance requirements.

Finally, expanding into underserved geographies through public-private partnerships and capacity-building initiatives will unlock new growth opportunities. By tailoring product portfolios to local clinical needs and price sensitivities, organizations can strengthen their market presence and contribute to global health security initiatives.

Rigorous Research Methodology Leveraging Data Collection, Analysis Techniques, and Validation Processes Underpinning the Infectious Diseases Diagnostics Market Study

This study synthesizes insights from extensive secondary research, including examination of peer-reviewed journals, regulatory publications, and corporate disclosures. To validate findings, structured interviews were conducted with senior executives, laboratory directors, and key opinion leaders across diagnostics, public health, and research institutions. Quantitative data points were triangulated with real-world evidence from case studies and pilot implementations to ensure accuracy and relevance.

Analytical techniques encompassed comparative benchmarking of assay performance, scenario analysis to assess tariff impact under various trade regimes, and qualitative assessment of emerging technology pipelines. A multi-stage validation process was employed, encompassing internal peer review, expert advisory board feedback, and cross-referencing with regional regulatory updates. This rigorous approach ensures that the conclusions and recommendations reflect both current market realities and anticipated industry trajectories.

Conclusive Insights Highlighting Key Findings, Market Implications, and Strategic Considerations for Stakeholders in Infectious Disease In-Vitro Diagnostics

In conclusion, the infectious diseases in-vitro diagnostics sector is poised at a critical juncture, driven by technological breakthroughs, shifting regulatory landscapes, and evolving trade policies. As laboratories and manufacturers adapt to new tariff environments, strategic realignments in sourcing and production will become increasingly important. The segmentation insights underscore the necessity for diversified portfolios, spanning instruments, reagents, and digital services, to meet heterogeneous end-user demands.

Regional dynamics reveal that while established markets will continue to benefit from advanced diagnostic infrastructures, high-growth potential lies in emerging economies that are scaling up screening and surveillance capabilities. Ultimately, success in this market will depend on the ability to integrate innovative assay platforms with robust data analytics, maintain compliance amidst tightening regulations, and pursue agile partnerships that drive value across the diagnostic continuum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of portable isothermal amplification systems supporting field deployment during epidemic outbreaks
  • 5.2. Adoption of CRISPR-based diagnostics revolutionizing point-of-care pathogen detection with high specificity
  • 5.3. Rise of decentralized near-patient testing solutions enabling rapid antimicrobial resistance profiling at the bedside
  • 5.4. Expansion of digital immunoassay platforms improving sensitivity in early sepsis biomarker identification
  • 5.5. Integration of multiplexed PCR assays accelerating simultaneous detection of emerging respiratory viruses in clinical settings
  • 5.6. Emergence of artificial intelligence-driven pattern recognition in automated microbiology workflows enhancing throughput
  • 5.7. Growth of microfluidic lab-on-a-chip devices facilitating on-site detection of vector-borne diseases in remote regions
  • 5.8. Increasing use of next-generation sequencing for comprehensive pathogen surveillance in hospital infection control
  • 5.9. Shifting reimbursement policies boosting adoption of high-throughput blood culture diagnostics in large healthcare networks
  • 5.10. Collaboration between diagnostics and pharmaceutical companies driving companion IVD tests for targeted antiviral therapies

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Infectious Diseases In-Vitro Diagnostics Market, by Product

  • 8.1. Introduction
  • 8.2. Instruments
    • 8.2.1. Automated Culture Systems
    • 8.2.2. Immunoassay Instruments
    • 8.2.3. PCR Instruments
  • 8.3. Reagents & Kits
    • 8.3.1. Immunoassay Kits
    • 8.3.2. Microbial Culture Media
    • 8.3.3. PCR Reagents
  • 8.4. Software & Services
    • 8.4.1. Consulting Services
    • 8.4.2. Data Management Software
    • 8.4.3. Maintenance & Support Services

9. Infectious Diseases In-Vitro Diagnostics Market, by Technology

  • 9.1. Introduction
  • 9.2. Immunoassays
    • 9.2.1. Chemiluminescence Immunoassay
    • 9.2.2. Enzyme Linked Immunosorbent Assay
    • 9.2.3. Fluorescence Immunoassay
    • 9.2.4. Lateral Flow Assay
  • 9.3. Microbiology Culture
  • 9.4. Molecular Diagnostics
    • 9.4.1. Isothermal Amplification
    • 9.4.2. Next Generation Sequencing
    • 9.4.3. Polymerase Chain Reaction

10. Infectious Diseases In-Vitro Diagnostics Market, by Pathogen

  • 10.1. Introduction
  • 10.2. Bacterial
    • 10.2.1. Enterobacteriaceae
    • 10.2.2. Mycobacterium Tuberculosis
    • 10.2.3. Staphylococcus Aureus
  • 10.3. Fungal
  • 10.4. Parasitic
  • 10.5. Viral
    • 10.5.1. Hepatitis Virus
    • 10.5.2. Human Immunodeficiency Virus
    • 10.5.3. Influenza Virus

11. Infectious Diseases In-Vitro Diagnostics Market, by Application

  • 11.1. Introduction
  • 11.2. Diagnosis
  • 11.3. Epidemiological Surveillance
  • 11.4. Monitoring
  • 11.5. Screening

12. Infectious Diseases In-Vitro Diagnostics Market, by End User

  • 12.1. Introduction
  • 12.2. Academic Research Institution
  • 12.3. Clinic
  • 12.4. Hospital
  • 12.5. Laboratory

13. Americas Infectious Diseases In-Vitro Diagnostics Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Becton, Dickinson and Company
    • 16.3.3. Bio-Rad Laboratories, Inc.
    • 16.3.4. bioMerieux SA
    • 16.3.5. Danaher Corporation
    • 16.3.6. DiaSorin S.p.A
    • 16.3.7. Epitope Diagnostics, Inc.
    • 16.3.8. F. Hoffmann La-Roche Ltd.
    • 16.3.9. Grifols, S.A.
    • 16.3.10. Hologic, Inc.
    • 16.3.11. Illumina, Inc.
    • 16.3.12. InBios International, Inc.
    • 16.3.13. Koninklijke Philips N.V.
    • 16.3.14. Merck KGaA
    • 16.3.15. Meril Life Sciences Pvt. Ltd.
    • 16.3.16. OraSure Technologies, Inc.
    • 16.3.17. Qiagen N.V.
    • 16.3.18. Quest Diagnostics
    • 16.3.19. Quidel Corporation
    • 16.3.20. Siemens Healthineers AG
    • 16.3.21. Sysmex Corporation
    • 16.3.22. Thermo Fisher Scientific Inc.
    • 16.3.23. Trinity Biotech PLC
    • 16.3.24. Vela Diagnostics

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 26. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 28. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIAL CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIAL CULTURE MEDIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY CULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MYCOBACTERIUM TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MYCOBACTERIUM TUBERCULOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 225. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 226. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 249. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 251. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 252. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 255. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 256. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 257. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS D